We've found
161,353
archived clinical trials in
Cancer
We've found
161,353
archived clinical trials in
Cancer
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Updated: 12/31/1969
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Updated: 12/31/1969
A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Updated: 12/31/1969
A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Updated: 12/31/1969
A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Updated: 12/31/1969
A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Updated: 12/31/1969
A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Updated: 12/31/1969
A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Updated: 12/31/1969
A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Updated: 12/31/1969
A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
